Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15720MR)

This product GTTS-WQ15720MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15720MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7993MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ13761MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ983MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ10439MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ13377MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10366MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ5801MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ15565MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW